Clinical Protocol & Data Management (CPDM) functions at Moffitt Cancer Center (MCC) include 1) trial design, development, and conduct; 2) oversight of safety and compliance; 3) ensuring data quality and education of personnel; and 4) appropriate accrual of women and minorities. A collaborative team of approximately 190 CPDM professionals provides centralized management and support of all types of clinical trials, including investigator-initiated (IITs), industry or other sponsor-initiated, Experimental Therapeutics Clinical Trials Network (ET-CTN), and National Clinical Trials Network (NCTN). CPDM support for members includes: protocol development; budget development and contracting; regulatory and IND/IDE management; protocol activation; patient enrollment; coordination of study-related patient care; research drug administration and care services; correlative science (pharmacokinetics/pharmacodynamics) sample coordination; data collection and reporting; monitoring of IIT studies and data and safety monitoring through the Protocol Monitoring Committee (PMC) and Data Safety & Monitoring (DSM) Committee; audit preparation and coordination; minority outreach and navigation for accrual to clinical trials; clinical trials management system (CTMS, OnCore) administration and reporting; staff workload management; and staff education and training. During the review period (FY2011-2015), the CPDM team successfully accrued and coordinated a combined total of 11,851 patients to clinical interventional trials (therapeutic, prevention, and supportive care), including accrual at affiliate sites. CPDM provides centralized safety and compliance oversight to members through timely monitoring of investigator-initiated interventional trials, coordination of the PMC, and corporate compliance audits of MCC clinical research trials, policies, and processes. Results of monitoring and audits are utilized by the PMC for comprehensive review. MCC has developed and maintains proactive efforts to provide programs and services to women, minorities, and other underserved populations through culturally and linguistically relevant care, education, and internal and community outreach. Faculty members conduct research on minority health disparities, informing these programs and services. In addition, the ACD for Clinical Science and the VP of Diversity and Community Relations co-lead a multi-disciplinary Minority Clinical Research Committee to address issues related to minority accrual at MCC. CPDM resources are closely integrated in these efforts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-20
Application #
9419805
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-02-01
Budget End
2019-01-31
Support Year
20
Fiscal Year
2018
Total Cost
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Karolak, Aleksandra; Markov, Dmitry A; McCawley, Lisa J et al. (2018) Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues. J R Soc Interface 15:
Liu, Ying; Wang, Hua; Li, Qian et al. (2018) Radiologic Features of Small Pulmonary Nodules and Lung Cancer Risk in the National Lung Screening Trial: A Nested Case-Control Study. Radiology 286:298-306
Padron, Eric; Ball, Markus C; Teer, Jamie K et al. (2018) Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood 131:2402-2405
Verduzco, Daniel; Kuenzi, Brent M; Kinose, Fumi et al. (2018) Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines. Mol Cancer Ther 17:73-83
Lee, Morgan S; Tyson, Dinorah Martinez; Gonzalez, Brian D et al. (2018) Anxiety and depression in Spanish-speaking Latina cancer patients prior to starting chemotherapy. Psychooncology 27:333-338
Correa, John B; Brandon, Karen O; Meltzer, Lauren R et al. (2018) Electronic cigarette use among patients with cancer: Reasons for use, beliefs, and patient-provider communication. Psychooncology 27:1757-1764
Divakaran, Anand; Talluri, Siva K; Ayoub, Alex M et al. (2018) Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor. J Med Chem 61:9316-9334
de Mingo Pulido, Álvaro; Gardner, Alycia; Hiebler, Shandi et al. (2018) TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell 33:60-74.e6
Li, Gongbo; Boucher, Justin C; Kotani, Hiroshi et al. (2018) 4-1BB enhancement of CAR T function requires NF-?B and TRAFs. JCI Insight 3:
McIntyre, Jessica; Jiménez, Julio; Rivera, Yonaira M et al. (2018) Comparison of Health Communication Channels for Reaching Hispanics About Biobanking: a Pilot Trial. J Cancer Educ 33:833-841

Showing the most recent 10 out of 1254 publications